Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan
| Autor: | Daisuke Yabe, Hideki Origasa, Hirotaka Watada, Takashi Kadowaki, Iichiro Shimomura, Hiroko Higashiyama, Keisuke Tobe, Kristy Iglay, Shigeru Tokita, Yutaka Seino |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | BMJ Open Diabetes Research & Care, Vol 8, Iss 2 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2020-0013 2052-4897 |
| DOI: | 10.1136/bmjdrc-2020-001361 |
| Popis: | Introduction To investigate factors affecting glycemic control, oral antidiabetic drug (OAD) treatment distribution and self-care activities among patients with type 2 diabetes mellitus (T2DM) who newly initiate OAD monotherapy in a real-world setting in Japan.Research design and methods A Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND) is an ongoing, prospective, observational cohort study with follow-up at 6, 12, 18 and 24 months. Primary objectives include OAD treatment patterns (cross-sectional and longitudinal) among diabetes specialists versus non-specialists; adherence to diabetes self-care activities; quality of life; treatment satisfaction among patients and target attainment rates of parameters, including glycated hemoglobin. Here, we present the study design and baseline data.Results Of 1506 patients enrolled (June 2016–May 2017; 174 sites in Japan), 1485 were included in the baseline analysis (617 treated by specialists, 868 by non-specialists). Most patients were prescribed dipeptidyl peptidase-4 inhibitors (DPP-4Is) (specialist vs non-specialist, 54.1% vs 57.1%), then sodium-glucose cotransporter 2 inhibitors (13.9% vs 22.2%), metformin (20.3% vs 12.9%) and other OADs ( |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|